E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of tezepelumab compared with placebo in reducing the prescribed OCS maintenance dose in patients with asthma requiring chronic treatment with maintenance OCS in addition to high dose ICS plus LABA |
|
E.2.2 | Secondary objectives of the trial |
Key Secondary Objective:
1)To evaluate the effect of tezepelumab compared with placebo on asthma exacerbations
Other Secondary Objectives:
1) To evaluate the effect of tezepelumab compared with placebo on the prescribed, OCS daily maintenance dose
2)To evaluate the effect of tezepelumab compared with placebo on Pre-BD lung function
3)To assess the effect of tezepelumab compared with placebo with regards to asthma symptoms and other asthma control metrics
4)To assess the effect of tezepelumab compared with placebo with regards to asthma related and general health-related quality of life
5)To evaluate the efficacy of tezepelumab compared with placebo on health resource
utilization and productivity loss due to asthma
6)To assess the effect of tezepelumab on biomarkers
7)To evaluate the pharmacokinetics (PK) and immunogenicity of tezepelumab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1)Subject must be 18 to 80 years of age inclusive at the time of signing the informed consent form
2)Subjects must have received a physician-prescribed medium- or highdose ICS as per GINA guideline for at least 12 months
3)Subjects must have received physician prescribed LABA and high dose ICS (total daily dose >500μg fluticasone propionate dry powder
formulation equivalent) for at least 3 months prior to visit 1. The ICS and LABA can be parts of a combination product, or given by separate
inhalers.
4)Additional maintenance asthma controller medications are allowed according to standard practice of care i.e., leukotriene receptor antagonists (LTRAs), theophylline, long-acting muscarinic antagonists (LAMAs), secondary ICS and cromones. The use of these medications must be documented for at least 3 months
5)Subjects must have received OCS for the treatment of asthma for at least 6 months prior to visit 1 and on a stable dose of between ≥ 7.5 to ≤
30mg (prednisone or prednisolone equivalent) daily or daily equivalent for at least 1 month. The OCS dose may be administered every other
day(or different doses every other day); Average dose over two days = The daily dose.
6)Morning pre-bronchodilator (BD) FEV1 must be < 80% predicted normal
7)Subjects must have evidence of asthma as documented by post-BD (albuterol/salbutatomol) reversibility of FEV1 ≥12% and ≥200 mL (15-30 min after administration of 4 puffs of albuterol/salbutamol), documented either in the previous 12 months or at screening
8)Subjects must have a history of at least 1 asthma exacerbation event within 12 months
9)Subject must have received the optimized OCS dose for at least 2 weeks prior to randomization
10)Minimum 10 days compliance with the morning and evening eDiary completion and OCS,ICS,LABA as well as other asthma controller medications as captured in the eDiary during the 14 days prior to randomization |
|
E.4 | Principal exclusion criteria |
1)Any clinically important pulmonary disease other than asthma (e.g. active lung infection, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
2)Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Affect the safety of the subject throughout the study Influence the findings of the study or the interpretation Impede the subject's ability to complete the entire duration of study
3)History of cancer: Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to visit 1.Subjects who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to visit 1
4)History of a clinically significant infection, including upper or lower respiratory tract infection (URTI and LRTI, respectively), requiring treatment with antibiotics or antiviral medications
finalized < 2 weeks before screening or during the run-in period.
5)A helminth parasitic infection diagnosed within 6 months prior to visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
6)Current smokers or subjects with smoking history ≥ 10 pack-years and subjects using vaping products, including electronic cigarettes. Former smokers with a smoking history of <10 pack years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to visit 1 to be eligible.
7)History of chronic alcohol or drug abuse within 12 months
8)Tuberculosis requiring treatment within the 12 months
9)History of any known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
10)Major surgery within 8 weeks prior to visit 1 or planned surgical procedures requiring general anaesthesia or in-subject status for >1 day during the conduct of the study.
11)Clinically significant asthma exacerbation, in the opinion of the Investigator, including those requiring use of systemic corticosteroids or increase in the maintenance dose of OCS within 30 days prior to to visit 1
12) During the optimization period, asthma control reached at an OCS dose of <7.5mg or >30mg and/or 3 consecutive dose reductions after which asthma control was still obtained
13)Evidence of clinically significant infection or subject receiving treatment with antibiotics or antiviral meidcations |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Categorized percent reduction from baseline in the daily OCS dose at Week 48 while not losing asthma control
The categories for percent change from baseline in daily OCS dose are defined as:
1. ≥90% to ≤100% reduction
2. ≥75% to <90% reduction
3. ≥50% to <75% reduction
4. >0% to <50% reduction
5. no change or any increase |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key Secondary Endpoint: Annualized asthma exacerbation rate (AAER)
Other Secondary Endpoints:
1a)Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 48
1b)Proportion of subjects with daily OCS dose ≤5 mg at Week 48
1c)Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 48
2)Change from baseline in Pre-bronchodilator forced expiratory volume in 1 second (FEV1)
3a)Change from baseline in weekly mean daily Asthma Symptom Score as captured in the daily Asthma Symptom Diary (ASD
3b)Change from baseline in weekly mean rescue medication use
3c) Change from baseline in weekly mean home peak expiratory flow (morning and evening)
3d) Change from baseline in weekly mean number of night-time awakening due to asthma
3e) Change from baseline in Asthma Control Questionnaire 6 (ACQ-6) score
4a)Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) total score
4b)Change from baseline in European Quality of Life – 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score
5a) Number of asthma specific resource utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications)
5b) Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questionnaire (WPAI+CIQ)
6a)Change from baselin in FENO
6b)Change from baseline peripheral blood eosinophils and total IgE
7a) PK: Serum trough concentrations
7b)Immunogenicity: Incidence of anti-drug antibodies (ADA) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Key Secondary Endpoint: Baseline to Week 48
Other Secondary Endpoints:
1)Week 48
2)Baseline, Week 48
3)Baseline, Week 48
4)Baseline, Week 48
5)Week 48
6)Baseline, Week 48
7)Baseline to Week 48 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Germany |
Korea, Republic of |
Poland |
Turkey |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 19 |